In a startling about-face, Roche (RHHBY) has agreed to release the recipe for a liquid solution that Dutch laboratories need to run a coronavirus test, after initially refusing to do so and causing an outcry among lawmakers and the media in the Netherlands.
A fracas erupted earlier this week due to a shortage of Roche tests, which are used on equipment made by the company. However, testing facilities lack enough of a solution —lysis buffer, which is used to break open cells — but the company balked at making the formula available so that others could produce the solution and run tests.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Very out of context, spelling etc – “Roche Tov!”